Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
All investments in healthcare businesses progressing as planned to further accelerate growth
Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT
The report summarises the business and highlights for 2018 and gives insights into the company’s strategy.
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
The combination of the two companies will create a leader in cell-based cancer immunotherapy, Kiadis said. It also further expands Kiadis’ toehold in the United States.
Promore Pharma AB calls for Annual General Meeting Tuesday 21 May 2019 at 2 pm at Wenner-Gren Center, Biblioteket, plan 24, Sveavägen 166, in Stockholm.
CEVEC Pharmaceuticals GmbH announced the successful closing of a Series D financing round with new and existing investors.
BioArctic AB announced that the Annual Report for the 2018 fiscal year has been published.
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a longer time.
The company announced it is seeking authorization to pursue both an auction and sale under the U.S. Bankruptcy Code.